Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;132(7):902-915.
doi: 10.1111/1471-0528.18101. Epub 2025 Feb 19.

Associations of Antenatal Corticosteroids With Neurodevelopment in Children Aged 27-30 Months: A Population-Based Cohort Study

Collaborators, Affiliations

Associations of Antenatal Corticosteroids With Neurodevelopment in Children Aged 27-30 Months: A Population-Based Cohort Study

Emily M Frier et al. BJOG. 2025 Jun.

Abstract

Objective: To examine the associations of antenatal corticosteroid (ACS) exposure with neurodevelopment in early childhood, and how these vary with gestational age at birth.

Design: Population-based cohort study.

Setting: Scotland, UK.

Population: 285 637 singleton children born at 28-41 weeks' gestation, between 1st January 2011 and 31st December 2017, who underwent health reviews at 27-30 months of age.

Methods: Logistic and linear regression analyses, stratified by gestation at birth (28-33, 34-36, 37-38 and 39-41 weeks' gestation), were used to evaluate the associations between ACS exposure and neurodevelopmental outcomes, and adjusted for maternal age, body mass index, diabetes, antenatal smoking, parity, neighbourhood deprivation, birth year, child sex and age at review.

Main outcome measures: Practitioner-identified concerns about any neurodevelopmental domain, and the average of five domain scores on neurodevelopmental milestones from the parent-rated Ages and Stages Questionnaire (ASQ-3).

Results: After adjustment for covariates, ACS exposure was associated with reduced neurodevelopmental concerns in children born at 28-33 weeks' gestation (OR = 0.79, 95% CI = 0.62-0.999) and with increased neurodevelopmental concerns in children born at 34-36 weeks' gestation (OR = 1.11, 95% CI = 1.01-1.21). No independent associations emerged in children born at later gestations. ACS exposure was not associated with ASQ-3 scores in any gestational age group.

Conclusions: In early childhood, ACS exposure was associated with statistically significantly reduced neurodevelopmental concerns in children born at 28-33 weeks' gestation, and with statistically significantly increased neurodevelopment concerns in children born at 34-36 weeks' gestation. However, the effect sizes of these associations were small. No independent associations were found between ACS exposure and neurodevelopment in term-born children.

Keywords: antenatal corticosteroids; neurodevelopment; preterm birth.

PubMed Disclaimer

Conflict of interest statement

The Co‐OPT ACS study is funded through a Wellcome Trust Clinical Career Development Fellowship grant (Funding Reference number 209560/Z/17) awarded to SJS. ML‐P is supported by grants from the Academy of Finland (330206). FD is supported by the Swiss National Science Foundation (P500PM_206634) and the Bangeter‐Rhyner Foundation. HZ is supported by a UNSW Scientia Program Award. DB is supported by a National Health and Medical Research Council Investigator Grant (GTN1175744). Research at Murdoch Children's Research Institute (DB, JEM) is supported by the Victorian Government's Operational Infrastructure Program. KD is funded by Health Education England (HEE)/NIHR. CG‐B is supported by research grants from NHLBI, NICHD and NIHMD, and has received research funding from HealthCore Inc/SERA Prognostics Inc. and MIRVIE Inc. LHP is supported by a Borregaard Clinical Ascending Investigator Grant from the Novo Nordisk Foundation (NNF18OC0054457). JPV is supported by an Australian National Health and Medical Research Council (NHMRC) Investigator grant (GNT1194248). EMcG acknowledges support of the NIHR North West Coast Scholars' Programme. RMR acknowledges the support of the British Heart Foundation (RE/18/5/34216). The remaining authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Derivation of the study cohort. “Practitioner‐assessed ND” refers to children with complete outcome data on practitioner concern about neurodevelopment and “ASQ‐3 ND score” refers to children with complete data on ASQ‐3 neurodevelopment score. ACS, antenatal corticosteroids; ASQ‐3, Ages and Stages Questionnaire Third Edition; n = number of children; ND, neurodevelopment.

Similar articles

References

    1. McGoldrick E., Stewart F., Parker R., and Dalziel S. R., “Antenatal Corticosteroids for Accelerating Fetal Lung Maturation for Women at Risk of Preterm Birth,” Cochrane Database of Systematic Reviews 12 (2020): CD004454, 10.1002/14651858.CD004454.pub4. - DOI - PMC - PubMed
    1. Frier E. M., Lin C., Reynolds R. M., et al., “Consortium for the Study of Pregnancy Treatments (Co‐OPT): An International Birth Cohort to Study the Effects of Antenatal Corticosteroids,” PLoS One 18, no. 3 (2023): e0282477, 10.1371/journal.pone.0282477. - DOI - PMC - PubMed
    1. Ninan K., Gojic A., Wang Y., et al., “The Proportions of Term or Late Preterm Births After Exposure to Early Antenatal Corticosteroids, and Outcomes: Systematic Review and Meta‐Analysis of 1.6 Million Infants,” BMJ 382 (2023): e076035, 10.1136/bmj-2023-076035. - DOI - PMC - PubMed
    1. Jobe A. H., “Antenatal Corticosteroids‐A Concern for Lifelong Outcomes,” Journal of Pediatrics 217 (2020): 184–188, 10.1016/j.jpeds.2019.09.015. - DOI - PubMed
    1. Reynolds R. M., “Glucocorticoid Excess and the Developmental Origins of Disease: Two Decades of Testing the Hypothesis – 2012 Curt Richter Award Winner,” Psychoneuroendocrinology 38, no. 1 (2013): 1–11, 10.1016/j.psyneuen.2012.08.012. - DOI - PubMed

Substances